Inovação tecnológica: um estudo sobre patentes em tuberculose pulmonar

Abstract

The patent document is an important source of technological information. The use of this source of information allows us to identify the main technological innovation topics listed to pulmonary tuberculosis, disease responsible for the largest cause of death from infectious disease in the world. The dissertation used patent data to identify patent applications on the theme of pulmonary tuberculosis from 2003 to 2013. The objectives were the description of requests for pulmonary tuberculosis patents under the framework of the International Patent Classification (IPC); technological focus; the geographical distribution of countries which have made the priority registration; the applicant and the analysis of the annual trend of patent applications in the study period. This research was characterized as a descriptive study, exploratory identification of patent applications that uses the sources of technological information available in the database Derwent Innovations Index. The quantity of search patent families using the phrase "pulmonary tuberculosis" was 2.028. The thematic trend of innovation in an analysis of the classifications of patent families according to the CIP shows the research aimed to Section Human Needs, at the class level: Medical Science or Veterinary and Hygiene e; the subclass level: specific therapeutic activity of chemical compounds or medicinal preparations and preparations for medical purposes, odontologias or hygienic. It was observed that the classification dedicated to vaccines, not ranked among the codes of higher frequency subclass, showing that this feature against pulmonary tuberculosis has not been the target of research. The analysis showed the patent documents US supremacy patent applications, followed by Europe and China; Brazil's role in the scenario was unrepresentative. Regarding the categorization of patent depositors, the highlight is for companies in the pharmaceutical field with important contributions of Mondobiotech Lab, Astrazeneca and Glaxogroup; the category of Individual physical figure depositors in second place and the category University was the third largest depositor. Observing the annual trend of patent applications for the issue, the result presented with an average of 216,04 in the period, an increase of 7,52 per year, with a greater contribution in 2007 (264,47) and, after that, acceleration negative 5,11 per year.